Cargando…
Targeting the FGFR signaling pathway in cholangiocarcinoma: promise or delusion?
Cholangiocarcinoma (CCA) is a refractory cancer with limited treatment options and poorly understood molecular mechanisms underlying tumor development. The most effective treatment is surgical resection; however, patients are highly prone to recurrence. Moreover, considering that most patients are d...
Autores principales: | Wang, Jing, Xing, Xiaokang, Li, Qijun, Zhang, Ge, Wang, Tao, Pan, Hongming, Li, Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378714/ https://www.ncbi.nlm.nih.gov/pubmed/32754231 http://dx.doi.org/10.1177/1758835920940948 |
Ejemplares similares
-
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
por: Rizzo, Alessandro
Publicado: (2021) -
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
por: Kongpetch, Sarinya, et al.
Publicado: (2020) -
Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021) -
Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2021) -
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)